India Pharma Bulls Eye Biosimilars as Next Growth Leg; DRL, Cipla, Biocon Named

Unverified expert flags bullish momentum in Indian large-cap pharma, spotlighting biosimilars as an emerging margin driver, but offers no price targets, earnings anchors, or quantified risk metrics.

bt-corporate · 6/28/2026, 12:40:01 PM · Ask about this →